Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin Pharmaceutical through its subsidiaries provides analytical and diagnostic products and services in the area of carbohydrate biology.
Website: biomarin.com



Growth: Pretty weak revenue growth rate 4.0%, there is slowdown compared to average historical growth rates 15.7%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +22.3%. On average the margin is decreasing unsteadily. Gross margin is high, +82.0%. In the last quarter the company beat the estimated EPS, +50.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 3.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 10.3% higher than minimum and 49.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.2x by EV / Sales multiple , the company can be 5.3% undervalued

Key Financials (Download financials)

Ticker: BMRN
Share price, USD:  (0.0%)56.78
year average price 58.67  


year start price 63.93 2025-02-07

max close price 72.83 2025-03-27

min close price 51.46 2025-11-07

current price 56.78 2026-02-06
Common stocks: 192 032 000

Dividend Yield:  0.0%
FCF Yield LTM: 3.1%
EV / LTM EBITDA: 13.7x
EV / Sales: 3.0x
Margin (EBITDA LTM / Revenue): 22.3%
Fundamental value created in LTM:
Market Cap ($m): 10 904
Net Debt ($m): -1 478
EV (Enterprise Value): 9 426
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-01seekingalpha.com

The Right Play On BioMarin Pharmaceuticals

2026-01-31fool.com

Should You Buy BioMarin Pharmaceutical Before Feb. 18?

2026-01-26prnewswire.com

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

2026-01-16zacks.com

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

2026-01-13zacks.com

BMRN or TARS: Which Is the Better Value Stock Right Now?

2026-01-12seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12zacks.com

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

2025-12-22seekingalpha.com

BioMarin: Amicus Buyout Sparks My Enthusiasm

2025-12-22zacks.com

BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B

2025-12-19seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
filingDate 2025-10-27 2025-02-24 2024-02-26 2023-02-27 2022-02-25 2021-02-26
acceptedDate 2025-10-27 16:08:23 2025-08-05 13:03:48 2025-02-24 13:54:22 2024-10-31 15:01:13 2024-08-05 16:35:15 2024-04-26 13:59:34 2024-02-26 13:34:15 2023-11-02 14:53:00 2023-08-02 12:48:35 2023-04-28 13:23:34 2023-02-27 17:25:52 2022-10-28 13:44:57 2022-02-25 13:40:25 2021-02-26 15:16:19
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 825M 2 854M 746M 709M 649M 2 419M 586M 595M 596M 2 096M 505M 1 846M 1 860M
costOfRevenue 0 150M 580M 188M 145M 139M 532M 140M 128M 127M 503M 116M 471M 524M
grossProfit 0 675M 2 274M 557M 564M 509M 1 887M 446M 467M 470M 1 593M 389M 1 376M 1 336M
researchAndDevelopmentExpenses 0 161M 747M 185M 184M 205M 747M 191M 177M 172M 650M 158M 629M 628M
generalAndAdministrativeExpenses 0 110M 532M 145M 140M 0 404M 102M 100M 105M 373M 106M 354M 334M
sellingAndMarketingExpenses 0 122M 477M 109M 123M 0 488M 122M 116M 118M 450M 111M 405M 403M
sellingGeneralAndAdministrativeExpenses 0 232M 1 009M 253M 277M 223M 892M 231M 215M 223M 823M 217M 759M 738M
otherExpenses 0 5M 33M 5M -5M 205M 62M 4M 3M 16M -41M 16M 70M 14M
operatingExpenses 0 398M 1 789M 443M 460M 427M 1 701M 423M 408M 411M 1 432M 391M 1 458M 1 380M
costAndExpenses 0 549M 2 370M 632M 605M 567M 2 233M 563M 536M 537M 1 935M 507M 1 929M 1 904M
netInterestIncome 0 62M 41M 2M -5M -13M
interestIncome 0 19M 75M 18M 20M 19M 58M 16M 13M 12M 18M 5M 10M 17M
interestExpense 0 3M 13M 3M 4M 4M 17M 4M 4M 4M 16M 5M 15M 29M
depreciationAndAmortization 0 19M 96M 19M 26M 27M 104M 26M 25M 28M 102M 25M 108M 105M
ebitda 0 319M 651M 156M 162M 109M 307M 49M 100M 87M 265M 28M 47M 84M
ebit 0 554M 202M 163M -61M -22M
nonOperatingIncomeExcludingInterest 0 -70M -17M -2M -22M -22M
operatingIncome 0 277M 484M 114M 103M 82M 186M 23M 59M 59M 161M 3M -82M -43M
totalOtherIncomeExpensesNet 0 21M 58M 21M 12M 24M 3M 19M 3M -3M -11M -5M 7M -6M
incomeBeforeTax 27M 298M 542M 134M 132M 106M 189M 42M 71M 57M 150M -2M -75M -49M
incomeTaxExpense 0 57M 115M 28M 25M 17M 21M 1M 15M 6M 8M 5M -11M -903M
netIncomeFromContinuingOperations 0 427M 168M 142M -64M 854M
netIncomeFromDiscontinuedOperations 0 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0 0
netIncome 27M 241M 427M 106M 107M 89M 168M 40M 56M 51M 142M -7M -64M 854M
netIncomeDeductions 0 -7M 0 0 0 -8M
bottomLineNetIncome 0 434M 168M 142M -64M 862M
eps 0.14 1.25 2.25 0.57 0.56 0.47 0.89 0.21 0.3 0.27 0.76 -0.036 -0.35 4.75
epsDiluted 0.14 2.21 0.88 0.75 -0.35 4.53
weightedAverageShsOut 192M 191M 190M 190M 190M 189M 188M 188M 188M 187M 185M 186M 183M 181M
weightedAverageShsOutDil 192M 197M 197M 197M 201M 199M 192M 191M 195M 194M 189M 186M 183M 192M
fillingDate 2025-08-05 2024-10-31 2024-08-05 2024-04-26 2023-11-02 2023-08-02 2023-04-28 2022-10-28
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.818 0.747 0.796 0.785 0.76 0.785 0.788 0.77
ebitdaratio 0.387 0.21 0.183 0.168 0.083 0.168 0.146 0.055
operatingIncomeRatio 0.335 0.153 0.146 0.126 0.039 0.099 0.1 0.005
incomeBeforeTaxRatio 0.361 0.18 0.186 0.163 0.071 0.119 0.095 -0.004
netIncomeRatio 0.291 0.142 0.151 0.137 0.069 0.094 0.085 -0.013
epsdiluted 1.23 0.55 0.55 0.44 0.21 0.29 0.27 -0.036
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-08-05 2024-10-31 2024-08-05 2024-04-26 2023-11-02 2023-08-02 2023-04-28 2022-10-28
acceptedDate 2025-10-28 14:07:10 2025-08-05 13:03:48 2025-02-24 13:54:22 2024-10-31 15:01:13 2024-08-05 16:35:15 2024-04-26 13:59:34 2024-02-26 13:34:15 2023-11-02 14:53:00 2023-08-02 12:48:35 2023-04-28 13:23:34 2023-02-27 17:25:52 2022-10-28 13:44:57 2022-02-25 13:40:25 2021-02-26 15:16:19
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 250M 1 214M 943M 675M 972M 747M 755M 785M 694M 580M 725M 762M 587M 649M
shortTermInvestments 228M 218M 195M 255M 252M 300M 319M 340M 477M 572M 567M 512M 427M 416M
cashAndShortTermInvestments 1 478M 1 432M 1 138M 930M 1 224M 1 047M 1 074M 1 126M 1 171M 1 152M 1 292M 1 274M 1 014M 1 065M
netReceivables 790M 856M 661M 778M 691M 637M 634M 572M 610M 598M 461M 420M 373M 448M
inventory 1 382M 1 340M 1 233M 1 179M 1 184M 1 138M 1 107M 1 032M 976M 919M 894M 839M 777M 699M
otherCurrentAssets 204M 177M 202M 169M 160M 163M 141M 225M 193M 173M 105M 150M 110M 130M
totalCurrentAssets 3 855M 3 805M 3 232M 3 057M 3 260M 2 985M 2 956M 2 955M 2 950M 2 842M 2 751M 2 683M 2 274M 2 342M
propertyPlantEquipmentNet 1 038M 1 030M 1 043M 1 045M 1 053M 1 060M 1 066M 1 067M 1 067M 1 068M 1 073M 1 052M 1 035M 1 032M
goodwill 196M 196M 196M 196M 196M 196M 196M 196M 196M 196M 196M 196M 196M 196M
intangibleAssets 233M 240M 255M 261M 266M 280M 295M 302M 310M 326M 339M 354M 389M 417M
goodwillAndIntangibleAssets 429M 436M 451M 457M 462M 476M 491M 499M 507M 522M 535M 550M 585M 613M
longTermInvestments 513M 509M 521M 562M 568M 621M 611M 548M 386M 341M 334M 372M 508M 285M
taxAssets 1 509M 1 427M 1 489M 1 531M 1 545M 1 546M 1 546M 1 524M 1 509M 1 511M 1 505M 1 455M 1 450M 1 432M
otherNonCurrentAssets 271M 249M 251M 199M 180M 185M 172M 165M 144M 150M 176M 152M 152M 142M
totalNonCurrentAssets 3 760M 3 651M 3 757M 3 795M 3 807M 3 888M 3 886M 3 803M 3 613M 3 592M 3 624M 3 581M 3 730M 3 506M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 7 615M 7 456M 6 989M 6 851M 7 067M 6 873M 6 842M 6 758M 6 563M 6 434M 6 375M 6 264M 6 005M 5 848M
accountPayables 390M 311M 235M 312M 257M 594M 316M 301M 278M 265M 231M 207M 200M 191M
shortTermDebt 0 8M 23M 16M 506M 494M 494M 493M 8M 9M 0 9M 0 0
taxPayables 0 13M 13M 21M 19M 6M 3M 11M 18M 22M 16M 8M 1M 19M
deferredRevenue 0 0 1M 2M 2M -594M 5M -301M -286M 0 711 000 415 000 7M 152 000
otherCurrentLiabilities 409M 352M 132M 372M 284M 594M 235M 670M 597M 324M 236M 304M 259M 183M
totalCurrentLiabilities 798M 684M 607M 716M 1 067M 1 088M 1 177M 1 163M 597M 598M 589M 521M 546M 493M
longTermDebt 597M 596M 595M 595M 594M 594M 593M 593M 1 085M 1 084M 1 083M 1 082M 1 079M 1 075M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 163M 149M 98M 128M 119M 117M 120M 105M 98M 92M 100M 958M 114M 174M
totalNonCurrentLiabilities 760M 745M 724M 722M 713M 711M 713M 698M 1 183M 1 176M 1 183M 1 175M 1 193M 1 249M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 8M 31M 8M 11M 9M 9M 9M 8M 9M 10M 9M 10M 12M
totalLiabilities 1 558M 1 429M 1 331M 1 438M 1 781M 1 799M 1 890M 1 861M 1 780M 1 775M 1 772M 1 696M 1 739M 1 742M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 192 000 192 000 191 000 191 000 190 000 190 000 189 000 188 000 188 000 188 000 186 000 186 000 184 000 182 000
retainedEarnings 201M 232M -195M -320M -426M -533M -622M -642M -682M -738M -789M -789M -931M -862M
accumulatedOtherComprehensiveIncomeLoss -45M -45M 62M 5M 15M -13M -29M 6M -19M -11M -4M 31M 14M -16M
othertotalStockholdersEquity 5 901M 5 840M 5 728M 5 697M 5 619M 5 532M 5 484M 5 408M 5 327M
totalStockholdersEquity 6 057M 6 027M 5 658M 5 413M 5 286M 5 074M 4 952M 4 897M 4 783M 4 659M 4 603M 4 569M 4 266M 4 106M
totalEquity 6 057M 6 027M 5 658M 5 413M 5 286M 5 074M 4 952M 4 897M 4 783M 4 659M 4 603M 4 569M 4 266M 4 106M
totalLiabilitiesAndStockholdersEquity 7 615M 7 456M 6 851M 7 067M 6 873M 6 758M 6 563M 6 434M 6 264M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 615M 7 456M 6 989M 6 851M 7 067M 6 873M 6 842M 6 758M 6 563M 6 434M 6 375M 6 264M 6 005M 5 848M
totalInvestments 741M 727M 716M 817M 820M 300M 930M 888M 862M 913M 901M 885M 934M 702M
totalDebt 597M 604M 649M 603M 1 100M 1 088M 1 096M 1 086M 1 085M 1 084M 1 093M 1 091M 1 090M 1 087M
netDebt -653M -610M -293M -73M 127M 341M 341M 301M 391M 504M 369M 330M 502M 438M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-24 2024-02-26 2023-02-27 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 661M 634M 461M 373M 448M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 248M 429M 333M 264M 293M
otherPayables 13M 113M 102M 64M 102M
accruedExpenses 203M 6M 8M 6M 4M
capitalLeaseObligationsCurrent 0 9M 10M 10M 12M
capitalLeaseObligationsNonCurrent 31M 0 0 0 0
treasuryStock 0 0 0 0 -10M
additionalPaidInCapital 5 802M 5 612M 5 405M 5 192M 4 993M
otherTotalStockholdersEquity -11M -10M -9M -10M 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN BMRN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-08-05 2024-10-31 2024-08-05 2024-04-26 2023-11-02 2023-08-02 2023-04-28 2022-10-28
acceptedDate 2025-10-28 14:07:10 2025-08-05 13:03:48 2025-02-24 13:54:22 2024-10-31 15:01:13 2024-08-05 16:35:15 2024-04-26 13:59:34 2024-02-26 13:34:15 2023-11-02 14:53:00 2023-08-02 12:48:35 2023-04-28 13:23:34 2023-02-27 17:25:52 2022-10-28 13:44:57 2022-02-25 13:40:25 2021-02-26 15:16:19
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -31M 426M 427M 106M 107M 89M 168M 40M 56M 51M 142M -7M -64M 859M
depreciationAndAmortization 18M 19M 96M 19M 26M 27M 104M 26M 25M 26M 102M 25M 108M 105M
deferredIncomeTax -14M 33M 56M 12M 1M 285 000 -45M -15M 1M -6M -52M -4M -16M -889M
stockBasedCompensation 49M 48M 202M 43M 48M 58M 207M 48M 50M 54M 196M 55M 197M 190M
changeInWorkingCapital 119M -158M -216M 172M -67M -105M -337M 40M -63M -217M -96M 92M 66M -224M
accountsReceivables 49M -99M -58M -130 400M -53M -3M -190M 14M -7M -139M -82M 39M 66M -59M
inventory -26M -48M -64M -29 212M -31M -17M -157M -41M -42M -14M -68M -26M -35M -61M
accountsPayables 116M 6M -32M 68 073M 5M -59M 69M 81M 7M -32M 59M 74M 16M -69M
otherWorkingCapital -20M -17M -63M 91 711M 12M -26M -58M -14M -20M -32M -5M 5M 20M -36M
otherNonCashItems 226M -182M 8M -132M 182M 170M 62M -4M -111 000 18M -115M -2M 13M 45M
netCashProvidedByOperatingActivities 369M 185M 573M 221M 119M 47M 159M 136M 70M -74M 176M 158M 305M 85M
investmentsInPropertyPlantAndEquipment -34M -17M -85M -18M -22M -34M -108M -23M -23M -25M -132M -36M -96M -138M
acquisitionsNet -285M 0 0 0 0 0 0 24M 1M 310 000 0 0 0 -23M
purchasesOfInvestments -111M -113M -410M -157M -74M -122M -868M -283M -224M -220M -612M -153M -937M -538M
salesMaturitiesOfInvestments 99M 118M 633M 161M 186M 132M 865M 261M 276M 215M 620M 166M 691M 556M
otherInvestingActivites 0 -266 000 -2M 112M 10M -24M -1M -310 000 0
netCashUsedForInvestingActivites -331M -13M -16M 90M -14M -46M 30M -30M -23M
debtRepayment 0 0 -495M -18 000 -42 000 -606 000 -621 000 -1M -513 000
commonStockIssued 7000 8M 5M 29M 7M 4M 0 0 0
commonStockRepurchased 0 0 0 0 -17M -50M 0 -5M 0 0 0 0 0 -50M
dividendsPaid 0 0 0 0 0 -5M 0 0 0
otherFinancingActivites -2M -12M -9M 13M -50M 5M 13M -40M 8M
netCashUsedProvidedByFinancingActivities -2M -5M -499M 13M -43M -788 000 12M -41M 8M
effectOfForexChangesOnCash 739 000 -3M 5M -3M 3M 1 927M 1M 2M 3M 229 000 32 000 -747 000 -57 000 -1M
netChangeInCash 36M 165M 188M -297M 225M -8M 31M 91M 114M -144M 137M 142M -62M 212M
cashAtEndOfPeriod 1 250M 1 214M 943M 675M 972M 747M 755M 785M 694M 580M 725M 762M 587M 649M
cashAtBeginningOfPeriod 1 214M 1 049M 755M 972M 747M 755M 725M 694M 580M 725M 587M 620M 649M 437M
operatingCashFlow 369M 185M 573M 221M 119M 47M 159M 136M 70M -74M 176M 158M 305M 85M
capitalExpenditure -28M -17M -97M -21M -22M -34M -97M -23M -23M -25M -121M -36M -119M -138M
freeCashFlow 340M 168M 475M 200M 97M 13M 63M 112M 47M -99M 55M 122M 185M -52M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-24 2024-02-26 2023-02-27 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -853 000 0 103M -25M 90M
netCashProvidedByInvestingActivities 136M -111M -20M -366M -54M
netDebtIssuance -495M -2M -3M -3M 204M
longTermNetDebtIssuance -495M -2M -3M -3M 204M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 69M 69M 0 -50M
netCommonStockIssuance 0 69M 69M 0 -50M
commonStockIssuance 0 69M 69M 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -31M -86M -85M 3M 27M
netCashProvidedByFinancingActivities -526M -19M -19M -48 000 181M
incomeTaxesPaid 57M 0 0 18M 9M
interestPaid 10M 0 0 10M 12M

Earning call transcript

2025 q3
2025-10-27 ET (fiscal 2025 q3)
2025 q2
2025-08-04 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-19 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-05 ET (fiscal 2024 q2)
2024 q1
2024-04-24 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-31 ET (fiscal 2023 q2)
2023 q1
2023-04-26 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-10-26 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-10-27 20:08 ET
BioMarin Pharmaceutical reported for 2025 q3
SEC form 8
2025-10-27 20:08 ET
BioMarin Pharmaceutical published news for 2025 q3
SEC form 8
2025-08-04 20:04 ET
BioMarin Pharmaceutical reported for 2025 q2
SEC form 8
2025-08-04 20:04 ET
BioMarin Pharmaceutical published news for 2025 q2
SEC form 8
2025-05-16 11:54 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-16 11:54 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-16 11:54 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-16 11:54 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 10
2025-05-02 16:33 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 10
2025-05-02 00:00 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-01 20:08 ET
BioMarin Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-01 20:08 ET
BioMarin Pharmaceutical reported for 2025 q1
SEC form 10
2025-02-24 18:54 ET
BioMarin Pharmaceutical published news for 2024 q4
SEC form 10
2025-02-24 00:00 ET
BioMarin Pharmaceutical published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
BioMarin Pharmaceutical published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
BioMarin Pharmaceutical reported for 2024 q4
SEC form 10
2024-10-31 00:00 ET
BioMarin Pharmaceutical reported for 2024 q3
SEC form 8
2024-10-29 16:04 ET
BioMarin Pharmaceutical published news for 2024 q3
SEC form 8
2024-10-29 16:04 ET
BioMarin Pharmaceutical published news for 2024 q3
SEC form 10
2024-08-05 16:35 ET
BioMarin Pharmaceutical published news for 2024 q2
SEC form 8
2024-08-05 16:05 ET
BioMarin Pharmaceutical reported for 2024 q2
SEC form 8
2024-08-05 16:05 ET
BioMarin Pharmaceutical published news for 2024 q2
SEC form 10
2024-08-05 00:00 ET
BioMarin Pharmaceutical published news for 2024 q2
SEC form 10
2024-04-26 00:00 ET
BioMarin Pharmaceutical published news for 2024 q1
SEC form 8
2024-04-24 16:07 ET
BioMarin Pharmaceutical published news for 2024 q1
SEC form 8
2024-04-24 16:07 ET
BioMarin Pharmaceutical reported for 2024 q1
SEC form 10
2024-02-26 13:34 ET
BioMarin Pharmaceutical published news for 2023 q4
SEC form 10
2024-02-26 00:00 ET
BioMarin Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-22 16:06 ET
BioMarin Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-22 16:06 ET
BioMarin Pharmaceutical reported for 2023 q4
SEC form 10
2023-11-02 14:53 ET
BioMarin Pharmaceutical published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
BioMarin Pharmaceutical published news for 2023 q3
SEC form 8
2023-11-01 16:09 ET
BioMarin Pharmaceutical reported for 2023 q3
SEC form 10
2023-08-02 00:00 ET
BioMarin Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-31 16:05 ET
BioMarin Pharmaceutical reported for 2023 q2
SEC form 8
2023-07-31 00:00 ET
BioMarin Pharmaceutical published news for 2023 q2
SEC form 6
2023-05-30 16:11 ET
BioMarin Pharmaceutical published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
BioMarin Pharmaceutical published news for 2023 q1
SEC form 8
2023-04-26 00:00 ET
BioMarin Pharmaceutical published news for 2023 q1
SEC form 10
2023-02-27 00:00 ET
BioMarin Pharmaceutical reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
BioMarin Pharmaceutical reported for 2022 q4
SEC form 8
2023-01-11 00:00 ET
BioMarin Pharmaceutical published news for 2022 q4
SEC form 10
2022-10-28 00:00 ET
BioMarin Pharmaceutical reported for 2022 q3
SEC form 8
2022-10-26 00:00 ET
BioMarin Pharmaceutical reported for 2022 q3
SEC form 10
2022-08-04 00:00 ET
BioMarin Pharmaceutical reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
BioMarin Pharmaceutical reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
BioMarin Pharmaceutical reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
BioMarin Pharmaceutical reported for 2022 q1
SEC form 10
2022-02-25 00:00 ET
BioMarin Pharmaceutical published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
BioMarin Pharmaceutical published news for 2021 q4
SEC form 10
2021-10-29 00:00 ET
BioMarin Pharmaceutical published news for 2021 q3
SEC form 8
2021-10-27 00:00 ET
BioMarin Pharmaceutical published news for 2021 q3
SEC form 10
2021-07-30 00:00 ET
BioMarin Pharmaceutical published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
BioMarin Pharmaceutical published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
BioMarin Pharmaceutical published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
BioMarin Pharmaceutical published news for 2021 q1